Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354041 | 0.87 | CNR2 (0.50) | CRHBPCRHR2PTPN1KMT2AMEN1 | |
| SCHEMBL5354047 | 0.87 | CNR2 (0.50) | CRHBPCRHR2PTPN1KMT2AMEN1 | |
| SCHEMBL8725080 | 0.84 | CRHBP (0.48) | CRHBPCRHR2PTPN1MTNR1AMTNR1B | |
| SCHEMBL3168058 | 0.79 | KMT2A (0.59) | KMT2AMEN1TSHR | |
| SCHEMBL20274587 | 0.79 | KMT2A (0.59) | KMT2AMEN1TSHR | |
| SCHEMBL20826236 | 0.77 | HDAC4 (0.44) | KMT2AMEN1CNR2 | |
| SCHEMBL20826431 | 0.76 | KMT2A (0.44) | KMT2AMEN1 | |
| SCHEMBL20826237 | 0.75 | KMT2A (0.45) | KMT2AMEN1 | |
| SCHEMBL14445159 | 0.75 | KMT2A (0.42) | KMT2AMEN1 | |
| SCHEMBL8725168 | 0.73 | CRHBP (0.52) | CRHBPCRHR2PTPN1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173139-B2 | Enantioselective 1,4-addition of aromatic nucleophiles to α,β-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236438-A1 | Enantioselective 1,4-addition of aromatic nucleophiles to alpha,beta-unsaturated aldehydes using chiral organic catalysts | NAT1, AOX1, ALDH7A1 | CRHBP 4725/4885CRHR2 4806/4885PTPN1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.